Open an account

RVL Pharmaceuticals

RVLPQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket open · · Delayed 15 min
No price history for this range.

About RVLPQ

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The firm is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. The company operates in one business segment which focuses on developing and commercializing pharmaceutical products. The firm is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.

Employees
125
Headquarters
Bridgewater, New Jersey
Listed
Oct 12, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
rvlpharma.com

RVLPQ key statistics

Market cap
111
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
6.46K
Volume
3.00K
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

RVL Pharmaceuticals (RVLPQ) at a glance

RVL Pharmaceuticals (RVLPQ) last traded at $0.00, with a market cap of 111 and a price-to-earnings ratio of 0.00.

Volume so far is 3.00K shares, below the average of 6.46K shares a day.

Over the past year RVL Pharmaceuticals has ranged from $0.00 to $0.0001, and now sits 0% of the way up that range.

RVL Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY23 it reported -$0.24 per share against an estimate of -$0.116.

RVLPQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 13.1% on average.

  1. Q3 FY21: reported -$0.28 per share against an estimate of -$0.3245
  2. Q4 FY21: reported -$0.30 per share against an estimate of -$0.2747
  3. Q1 FY22: reported -$0.25 per share against an estimate of -$0.1769
  4. Q2 FY22: reported -$0.14 per share against an estimate of -$0.2137
  5. Q3 FY22: reported -$0.16 per share against an estimate of -$0.164
  6. Q4 FY22: reported -$0.18 per share against an estimate of -$0.1645
  7. Q1 FY23: reported -$0.12 per share against an estimate of -$0.1222
  8. Q2 FY23: reported -$0.24 per share against an estimate of -$0.116

Similar companies

Companies in the same industry as RVL Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.